Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study is being done because there are currently no approved and no commonly working
targeted therapies in anaplastic thyroid cancer (ATC). This is an area of urgent need for
patients, not just for approved treatments but also rationally-designed clinical trials
designed specifically for ATC. Patients diagnosed with anaplastic thyroid cancer have a very
high likelihood of dying because of their disease. As such there is a clear need for
improving therapy for ATC.